PRNewswire

May 26, 2026

Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout

read more →

PRNewswire

February 2, 2026

Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites

read more →

Genetic Engineering & Biotechnology News

June 1, 2026

Attacking Gout: Crystalys Sees Room for Its Dotinurad and Other Allopurinol Alternatives

read more →

The Bio Report

May 6, 2026

Addressing Treatment Gaps in Gout

read more →